Researchers at Kyoto University have developed an innovative non-opioid painkiller named ADRIANA that promises effective pain relief without the risk of addiction or serious side effects linked to traditional opioids. Unlike opioids, which target brain receptors and carry dangers such as respiratory failure and dependence, ADRIANA works by selectively blocking α2B-adrenoceptors, a novel pain pathway that enhances the body’s natural pain suppression mechanisms.
Clinical trials at Kyoto University Hospital have demonstrated that ADRIANA provides strong postoperative pain relief in lung cancer surgery patients, matching the effectiveness of morphine but without sedation, anxiety, or signs of addiction. Animal studies further support its safety profile, showing effective pain reduction without typical opioid-associated side effects.
With opioid overdoses continuing to claim tens of thousands of lives annually, ADRIANA offers hope for a safer alternative in pain management. A large-scale Phase II trial planned in the United States could pave the way for broader availability within the next few years. If successful, ADRIANA may become a game changer in treating acute and chronic pain, reducing reliance on opioids and improving quality of life for patients worldwide.
More than news- Its Icegate